BridgeBio Pharma
BBIO
BBIO
213 hedge funds and large institutions have $2.53B invested in BridgeBio Pharma in 2023 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 76 increasing their positions, 58 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
19% more funds holding
Funds holding: 179 → 213 (+34)
3% more call options, than puts
Call options by funds: $53.7M | Put options by funds: $52M
1.57% less ownership
Funds ownership: 96.72% → 95.15% (-1.6%)
Holders
213
Holding in Top 10
8
Calls
$53.7M
Puts
$52M
Top Buyers
| 1 | +$52.9M | |
| 2 | +$24.4M | |
| 3 | +$23.2M | |
| 4 |
LCM
Laurion Capital Management
New York
|
+$21.4M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$19.4M |
Top Sellers
| 1 | -$61.4M | |
| 2 | -$42.9M | |
| 3 | -$20M | |
| 4 |
AIG
American International Group
New York
|
-$16.8M |
| 5 |
BlackRock
New York
|
-$10.8M |